SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Piette J C)
 

Sökning: WFRF:(Piette J C) > (2010-2014) > EULAR recommendatio...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004036naa a2200565 4500
001oai:prod.swepub.kib.ki.se:121633240
003SwePub
008240913s2010 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1216332402 URI
024a https://doi.org/10.1136/ard.2010.1304762 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Bertsias, GK4 aut
2451 0a EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
264 c 2010-08-19
264 1b BMJ,c 2010
520 a To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations.MethodsThe authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and prognosis of NPSLE. A systematic literature search was performed and evidence was categorised based on sample size and study design.ResultsSystemic lupus erythematosus (SLE) patients are at increased risk of several neuropsychiatric manifestations. Common (cumulative incidence >5%) manifestations include cerebrovascular disease (CVD) and seizures; relatively uncommon (1–5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis. Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea). The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE. Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI (T1/T2, fluid-attenuating inversion recovery, diffusion-weighted imaging, enhanced T1 sequence). Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity. Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD.ConclusionsNeuropsychiatric manifestations in SLE patients should be first evaluated and treated as in patients without SLE, and secondarily attributed to SLE and treated accordingly.
700a Ioannidis, JPA4 aut
700a Aringer, M4 aut
700a Bollen, E4 aut
700a Bombardieri, S4 aut
700a Bruce, IN4 aut
700a Cervera, R4 aut
700a Dalakas, M4 aut
700a Doria, A4 aut
700a Hanly, JG4 aut
700a Huizinga, TWJ4 aut
700a Isenberg, D4 aut
700a Kallenberg, C4 aut
700a Piette, JC4 aut
700a Schneider, M4 aut
700a Scolding, N4 aut
700a Smolen, J4 aut
700a Stara, A4 aut
700a Tassiulas, I4 aut
700a Tektonidou, M4 aut
700a Tincani, A4 aut
700a van Buchem, MA4 aut
700a van Vollenhoven, Ru Karolinska Institutet4 aut
700a Ward, M4 aut
700a Gordon, C4 aut
700a Boumpas, DT4 aut
710a Karolinska Institutet4 org
773t Annals of the rheumatic diseasesd : BMJg 69:12, s. 2074-2082q 69:12<2074-2082x 1468-2060x 0003-4967
856u https://ard.bmj.com/content/69/12/2074.full.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:121633240
8564 8u https://doi.org/10.1136/ard.2010.130476

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy